Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Sulindac Plus Epirubicin in Advanced Melanoma
2006-006051-12Phase 2Terminated
- Sponsor
- Cancer Trials Ireland
- Start
- Nov 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulindac and epirubicin in melanoma, sponsored by Cancer Trials Ireland. Primary endpoint: Tumor response (CR, PR, SD). Started Nov 2006; status: terminated.
02
Drugs
sulindacepirubicin
03
Conditions
melanoma
Beyond the preview
Go deeper on 2006-006051-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006051-12.